APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Oral Anticoagulants (DOACs)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Direct Oral Anticoagulants (DOACs) Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchDirect Oral Anticoagulants (DOACs) Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Oral Anticoagulants (DOACs) Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Direct Oral Anticoagulants (DOACs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Oral Anticoagulants (DOACs) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Oral Anticoagulants (DOACs) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Direct Oral Anticoagulants (DOACs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Direct Oral Anticoagulants (DOACs) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Direct Oral Anticoagulants (DOACs) market include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Direct Oral Anticoagulants (DOACs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Direct Oral Anticoagulants (DOACs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Direct Oral Anticoagulants (DOACs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Direct Oral Anticoagulants (DOACs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Direct Oral Anticoagulants (DOACs) Segment by Company

Accord Healthcare

Apotex

Boehringer Ingelheim

Bristol Myers Squibb

Daiichi Sankyo

GlaxoSmithKline

Janssen Pharmaceuticals

Teva Pharmaceutical

Viatris

Bayer

Pfizer

Mylan

Sandoz

Direct Oral Anticoagulants (DOACs) Segment by Type

Oral Factor Xa Inhibitors

Direct Thrombin Inhibitors (DTIs)

Direct Oral Anticoagulants (DOACs) Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Direct Oral Anticoagulants (DOACs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Direct Oral Anticoagulants (DOACs) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Direct Oral Anticoagulants (DOACs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Direct Oral Anticoagulants (DOACs) significant trends, drivers, influence factors in global and regions.

6. To analyze Direct Oral Anticoagulants (DOACs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Direct Oral Anticoagulants (DOACs) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Direct Oral Anticoagulants (DOACs) industry.

Chapter 3: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Direct Oral Anticoagulants (DOACs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Direct Oral Anticoagulants (DOACs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Direct Oral Anticoagulants (DOACs) Industry Trends Table 2. Direct Oral Anticoagulants (DOACs) Industry Drivers Table 3. Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges Table 4. Direct Oral Anticoagulants (DOACs) Industry Restraints Table 5. Global Direct Oral Anticoagulants (DOACs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Direct Oral Anticoagulants (DOACs) Revenue Share by Company (2021-2026) Table 7. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Company (2021-2026) Table 9. Global Direct Oral Anticoagulants (DOACs) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Direct Oral Anticoagulants (DOACs) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Direct Oral Anticoagulants (DOACs) Key Company Manufacturing Base & Headquarters Table 12. Global Direct Oral Anticoagulants (DOACs) Company, Product Type & Application Table 13. Global Direct Oral Anticoagulants (DOACs) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Direct Oral Anticoagulants (DOACs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Factor Xa Inhibitors Table 18. Significant Companies of Direct Thrombin Inhibitors (DTIs) Table 19. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Type (2021-2026) Table 23. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Type (2027-2032) Table 24. Global Direct Oral Anticoagulants (DOACs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Direct Oral Anticoagulants (DOACs) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Direct Oral Anticoagulants (DOACs) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Type (2021-2026) Table 28. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pulmonary Embolism Table 30. Significant Companies of Deep Vein Thrombosis Table 31. Significant Companies of Atrial Fibrillation Table 32. Significant Companies of Other Table 33. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Application (2021-2026) Table 37. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Application (2027-2032) Table 38. Global Direct Oral Anticoagulants (DOACs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Direct Oral Anticoagulants (DOACs) Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Direct Oral Anticoagulants (DOACs) Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Application (2021-2026) Table 42. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Application (2027-2032) Table 43. Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026) & (K Units) Table 45. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021-2026) Table 46. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2027-2032) & (K Units) Table 47. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2027-2032) Table 48. Global Direct Oral Anticoagulants (DOACs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Direct Oral Anticoagulants (DOACs) Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Region (2021-2026) Table 51. Global Direct Oral Anticoagulants (DOACs) Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Region (2027-2032) Table 53. Global Direct Oral Anticoagulants (DOACs) Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Direct Oral Anticoagulants (DOACs) Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Direct Oral Anticoagulants (DOACs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Direct Oral Anticoagulants (DOACs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 58. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026) Table 59. Global Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032) & (K Units) Table 60. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2027-2032) Table 61. Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Direct Oral Anticoagulants (DOACs) Sales Value Market Share by Country (2021-2026) Table 63. Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Direct Oral Anticoagulants (DOACs) Sales Value Market Share by Country (2027-2032) Table 65. Accord Healthcare Company Information Table 66. Accord Healthcare Business Overview Table 67. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio Table 69. Accord Healthcare Recent Development Table 70. Apotex Company Information Table 71. Apotex Business Overview Table 72. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio Table 74. Apotex Recent Development Table 75. Boehringer Ingelheim Company Information Table 76. Boehringer Ingelheim Business Overview Table 77. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio Table 79. Boehringer Ingelheim Recent Development Table 80. Bristol Myers Squibb Company Information Table 81. Bristol Myers Squibb Business Overview Table 82. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio Table 84. Bristol Myers Squibb Recent Development Table 85. Daiichi Sankyo Company Information Table 86. Daiichi Sankyo Business Overview Table 87. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio Table 89. Daiichi Sankyo Recent Development Table 90. GlaxoSmithKline Company Information Table 91. GlaxoSmithKline Business Overview Table 92. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio Table 94. GlaxoSmithKline Recent Development Table 95. Janssen Pharmaceuticals Company Information Table 96. Janssen Pharmaceuticals Business Overview Table 97. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio Table 99. Janssen Pharmaceuticals Recent Development Table 100. Teva Pharmaceutical Company Information Table 101. Teva Pharmaceutical Business Overview Table 102. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio Table 104. Teva Pharmaceutical Recent Development Table 105. Viatris Company Information Table 106. Viatris Business Overview Table 107. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio Table 109. Viatris Recent Development Table 110. Bayer Company Information Table 111. Bayer Business Overview Table 112. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 114. Bayer Recent Development Table 115. Pfizer Company Information Table 116. Pfizer Business Overview Table 117. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 119. Pfizer Recent Development Table 120. Mylan Company Information Table 121. Mylan Business Overview Table 122. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio Table 124. Mylan Recent Development Table 125. Sandoz Company Information Table 126. Sandoz Business Overview Table 127. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio Table 129. Sandoz Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Direct Oral Anticoagulants (DOACs) Distributors List Table 133. Direct Oral Anticoagulants (DOACs) Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Direct Oral Anticoagulants (DOACs) Product Image Figure 2. Global Direct Oral Anticoagulants (DOACs) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Direct Oral Anticoagulants (DOACs) Sales (2021-2032) & (K Units) Figure 5. Global Direct Oral Anticoagulants (DOACs) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Direct Oral Anticoagulants (DOACs) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Factor Xa Inhibitors Image Figure 10. Direct Thrombin Inhibitors (DTIs) Image Figure 11. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Type (2021-2032) Figure 14. Global Direct Oral Anticoagulants (DOACs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Direct Oral Anticoagulants (DOACs) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Type (2021-2032) Figure 17. Pulmonary Embolism Image Figure 18. Deep Vein Thrombosis Image Figure 19. Atrial Fibrillation Image Figure 20. Other Image Figure 21. Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Application (2021-2032) Figure 24. Global Direct Oral Anticoagulants (DOACs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Direct Oral Anticoagulants (DOACs) Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Application (2021-2032) Figure 27. Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Direct Oral Anticoagulants (DOACs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032) & (US$ Million) Figure 32. North America Direct Oral Anticoagulants (DOACs) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Direct Oral Anticoagulants (DOACs) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032) & (US$ Million) Figure 38. South America Direct Oral Anticoagulants (DOACs) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Direct Oral Anticoagulants (DOACs) Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Direct Oral Anticoagulants (DOACs) Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Factor Xa Inhibitors
  • Direct Thrombin Inhibitors (DTIs)
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • Teva Pharmaceutical
  • Viatris
  • Bayer
  • Pfizer
  • Mylan
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032)
  4. 1.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume (2021-2032)
  5. 1.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Direct Oral Anticoagulants (DOACs) Market Dynamics
  1. 2.1 Direct Oral Anticoagulants (DOACs) Industry Trends
  2. 2.2 Direct Oral Anticoagulants (DOACs) Industry Drivers
  3. 2.3 Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges
  4. 2.4 Direct Oral Anticoagulants (DOACs) Industry Restraints
3 Direct Oral Anticoagulants (DOACs) Market by Company
  1. 3.1 Global Direct Oral Anticoagulants (DOACs) Company Revenue Ranking in 2025
  2. 3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Company (2021-2026)
  3. 3.3 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Company (2021-2026)
  4. 3.4 Global Direct Oral Anticoagulants (DOACs) Average Price by Company (2021-2026)
  5. 3.5 Global Direct Oral Anticoagulants (DOACs) Company Ranking (2024-2026)
  6. 3.6 Global Direct Oral Anticoagulants (DOACs) Company Manufacturing Base and Headquarters
  7. 3.7 Global Direct Oral Anticoagulants (DOACs) Company Product Type and Application
  8. 3.8 Global Direct Oral Anticoagulants (DOACs) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Direct Oral Anticoagulants (DOACs) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Direct Oral Anticoagulants (DOACs) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Direct Oral Anticoagulants (DOACs) Market by Type
  1. 4.1 Direct Oral Anticoagulants (DOACs) Type Introduction
  2. 4.1.1 Oral Factor Xa Inhibitors
  3. 4.1.2 Direct Thrombin Inhibitors (DTIs)
  4. 4.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type
  5. 4.2.1 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Direct Oral Anticoagulants (DOACs) Sales Value by Type
  9. 4.3.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Type (2021-2032)
5 Direct Oral Anticoagulants (DOACs) Market by Application
  1. 5.1 Direct Oral Anticoagulants (DOACs) Application Introduction
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application
  7. 5.2.1 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Direct Oral Anticoagulants (DOACs) Sales Value by Application
  11. 5.3.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Application (2021-2032)
  13. 5.3.3 Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Application (2021-2032)
6 Direct Oral Anticoagulants (DOACs) Regional Sales and Value Analysis
  1. 6.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2032)
  3. 6.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021-2026
  4. 6.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2027-2032)
  5. 6.3 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region (2027-2032)
  9. 6.5 Global Direct Oral Anticoagulants (DOACs) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032)
  12. 6.6.2 North America Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032)
  15. 6.7.2 Europe Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032)
  21. 6.9.2 South America Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2025 VS 2032
7 Direct Oral Anticoagulants (DOACs) Country-level Sales and Value Analysis
  1. 7.1 Global Direct Oral Anticoagulants (DOACs) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2032)
  4. 7.3.1 Global Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
  5. 7.3.2 Global Direct Oral Anticoagulants (DOACs) Sales by Country (2027-2032)
  6. 7.4 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 Apotex
  8. 8.2.1 Apotex Company Information
  9. 8.2.2 Apotex Business Overview
  10. 8.2.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
  12. 8.2.5 Apotex Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Bristol Myers Squibb
  20. 8.4.1 Bristol Myers Squibb Company Information
  21. 8.4.2 Bristol Myers Squibb Business Overview
  22. 8.4.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
  24. 8.4.5 Bristol Myers Squibb Recent Developments
  25. 8.5 Daiichi Sankyo
  26. 8.5.1 Daiichi Sankyo Company Information
  27. 8.5.2 Daiichi Sankyo Business Overview
  28. 8.5.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
  30. 8.5.5 Daiichi Sankyo Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Janssen Pharmaceuticals
  38. 8.7.1 Janssen Pharmaceuticals Company Information
  39. 8.7.2 Janssen Pharmaceuticals Business Overview
  40. 8.7.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
  42. 8.7.5 Janssen Pharmaceuticals Recent Developments
  43. 8.8 Teva Pharmaceutical
  44. 8.8.1 Teva Pharmaceutical Company Information
  45. 8.8.2 Teva Pharmaceutical Business Overview
  46. 8.8.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
  48. 8.8.5 Teva Pharmaceutical Recent Developments
  49. 8.9 Viatris
  50. 8.9.1 Viatris Company Information
  51. 8.9.2 Viatris Business Overview
  52. 8.9.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
  54. 8.9.5 Viatris Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Mylan
  68. 8.12.1 Mylan Company Information
  69. 8.12.2 Mylan Business Overview
  70. 8.12.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
  72. 8.12.5 Mylan Recent Developments
  73. 8.13 Sandoz
  74. 8.13.1 Sandoz Company Information
  75. 8.13.2 Sandoz Business Overview
  76. 8.13.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
  78. 8.13.5 Sandoz Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Direct Oral Anticoagulants (DOACs) Value Chain Analysis
  2. 9.1.1 Direct Oral Anticoagulants (DOACs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Direct Oral Anticoagulants (DOACs) Sales Mode & Process
  6. 9.2 Direct Oral Anticoagulants (DOACs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Direct Oral Anticoagulants (DOACs) Distributors
  9. 9.2.3 Direct Oral Anticoagulants (DOACs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst